Nuclear matrix protein-22: A prospective evaluation in a population at risk for bladder cancer. Results from the UroScreen study

BJU International

Volumn 110, Issue 5, 2012, Pages 699-708

  Huber, Severine ^a   Schwentner, Christian ^a   Taeger, Dirk ^b   Pesch, Beate ^b   Nasterlack, Michael ^c   Leng, Gabriele ^d   Mayer, Thomas ^c   Gawrych, Katarzyna ^b   Bonberg, Nadin ^b   Pelster, Martin ^a   Johnen, Georg ^b   Bontrup, Heike ^b   Wellhäußer, Harald ^e   Bierfreund, Hans Georg ^a   Wiens, Christian ^a   Bayer, Christian ^a   Eberle, Friedhelm ^c   Scheuermann, Bernd ^c   Kluckert, Mattias ^e   Feil, Gerhard ^a   Brüning, Thomas ^b   Stenzl, Arnulf ^a   more..

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c BASF SE   (Germany)

^d Bayer Industry Services GmbH and Co OHG   (Germany)

^e INSTITUT FÜR ARBEITSSCHUTZ DER DEUTSCHEN GESETZLICHEN UNFALLVERSICHERUNG IFA   (Germany)

Author keywords

bladder cancer; early detection; haematuria; NMP22; renal function

Indexed keywords

AROMATIC AMINE; CREATININE; MOLECULAR MARKER; NUCLEAR MATRIX PROTEIN 22;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER DIAGNOSIS; CANCER RISK; CANCER SCREENING; CHEMICAL INDUSTRY; CLINICAL EVALUATION; CONFIDENCE INTERVAL; CONTROLLED STUDY; CREATININE URINE LEVEL; CYSTOSCOPY; DIAGNOSTIC VALUE; ENDOSCOPY; FOLLOW UP; HEMATURIA; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; IMMUNOASSAY; KIDNEY CONCENTRATING CAPACITY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; OCCUPATIONAL EXPOSURE; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIMARY TUMOR; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENT CANCER; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TRANSURETHRAL RESECTION; URINALYSIS; URINE CYTOLOGY; UROGENITAL TRACT TUMOR; WORKER;

ADULT; AGED; AGED, 80 AND OVER; AMINES; EARLY DETECTION OF CANCER; ENVIRONMENTAL EXPOSURE; HEMATURIA; HUMANS; MIDDLE AGED; NUCLEAR PROTEINS; PROSPECTIVE STUDIES; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84864850026     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10883.x     Document Type: Article

References (33)

1. Arbeitsgemeinschaft Bevölkerungsbezogener Krebsregister in Deutschland: Krebs in Deutschland. 3.aktualisierte Ausgabe, Saarbrücken. 2002
2. Claude JC, Frentzel-Beyme RR, Kunz E,. Occupation and risk of cancer of the lower urinary tract among men. A case-control study. Int J Cancer 1988; 41: 371-9 (Pubitemid 18080790)
3. Pesch B, Haerting J, Ranft U, Klimpel A, Oelschlägel B, Schill W,. Occupational risk factors for urothelial carcinoma: agent-specific results from a case-control study in Germany. MURC Study Group. Mulitcenter Urothelial and Renal Cancer Study. Int J Epidemiol 2000; 2: 238-47 (Pubitemid 30209813)
4. Rehn L,. Blasengeschwülste bei Fuchsinarbeitern. Arch Klin Clin 1895; 50: 588-600
5. Schulte PA, Ringen K, Hemstreet GP, et al. Risk factors of BC in a cohort exposed to aromatic amines. Cancer 1986; 58: 2156-62 (Pubitemid 16008800)
6. Popp W, Schmieding W, Speck M, Vahrenholz C, Norpoth K,. Incidence of BC in a cohort of workers exposed to 4-chloro-o-toluidine while synthesizing chlordimeform. Br J Ind Med 1992; 49: 529-31
7. Stasik MJ,. Carcinomas of the urinary bladder in a 4-chloro-o-toluidine cohort. Int Arch Occup Environ Health 1988; 60: 21-4 (Pubitemid 18008241)
8. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, Palou-Redorta J, European Association of Urology (EAU). EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 2008; 54: 303-14. Epub 2008 Apr 30. Review
9. Herr HW, Donat SM, Dalbagni G,. Correlation of cystoscopy with histology of recurrent papillary tumors of the bladder. J Urol 2002; 168: 978-80
10. Mowatt G, Zhu S, Kilonzo M, et al. Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of BC. Health Technol Assess 2010; 14: 1-331
11. Feil G, Krause FS, Nelde HJ, Bichler K-H, Wechsel HW,. Diagnosis of transitional cell carcinoma (TCC) of the BC: comparison if urinary cytology, BTA TRAK test, and NMP22 assay. Anticancer Res 1999; 19: 5743 (abs)
12. Lahme S, Bichler K-H, Feil G, Krause S,. Comparison of cytology and nuclear matrix protein for the detection and follow-up of BC. Urol Int 2001; 66: 72-7 (Pubitemid 32172971)
13. Landman J, Chang Y, Kavaler E, Droller MJ, Liu BC-S,. Sensitivity and specificity of NMP22, telomerase, and BTA in the detection of human BC. J Urol 1998; 52: 398-402 (Pubitemid 28399904)
14. Ramakumar S, Bhuiyan J, Besse JA, et al. Comparison of screening methods in the detection of BC. J Urol 1999; 161: 388-94
15. Bunting P, Fleshner N, Kapusta L, Hersey K, Kotz L,. Detection of BC via non-invasive methods: a direct comparison of the NMP-22 and Immunocyt tests. J Urol 2000; 163 (Suppl.): 133-5
16. Zeger SL, Liang KY,. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986; 42: 121-30
17. Pesch B, Nasterlack M, Eberle F, et al. The role of haematuria in BC screening among men with former occupational exposure to aromatic amines. BJU Int 2011; 108: 546-52
18. Rodgers M, Nixon J, Hempel S, et al. Diagnostic tests and algorithms used in the investigation of haematuria: systematic reviews and economic evaluation. Health Technol Assess 2006; 10: iii-iv, xi-259
19. Habuchi T, Marberger M, Droller MJ, et al. Prognostic markers for BC: International Consensus Panel on bladder tumor markers. Urology 2005; 66 (Suppl. 1): 64-74 (Pubitemid 43049609)
20. Feil G, Bichler KH, Päulgen-Nelde HJ, et al. Urinzytologie beim Harnblasenkarzinom. Diagnostische Wertigkeit eines neuen immunologischen Fluoreszenztestes. Urologe A 2003; 42: 531-7
21. Rathert P,. Urinzytologie beim Harnblasenkarzinom: Kritische Wertung. Urologe A 2003; 42: 908-11 (Pubitemid 36958566)
22. HVBG (Hrsg). BK-DOK '99. Dokumentation des Berufskrankheiten-Geschehens in Deutschland. Sankt-Augustin. 2001
23. Lotan Y, Svatek RS, Sagalowsky AI,. Should we screen for bladder cancer in a high-risk population?: a cost per life-year saved analysis. Cancer 2006; 107: 982-90 (Pubitemid 44291147)
24. Budman LI, Kassouf W, Steinberg JR,. Biomarkers for detection and surveillance of bladder cancer. Can Urol Assoc J 2008; 2: 212-21
25. Zippe C, Pandrangi L, Agarwal A,. NMP22 is a sensitive, cost-effective test in patients at risk for BC. J Urol 1999; 161: 62-5 (Pubitemid 29422291)
26. Del Nero A, Esposito N, Currà A, et al. Evaluation of urinary level of NMP22 as a diagnostic marker for stage pTa-pT1 BC: comparison with urinary cytology and BTA test. Eur Urol 1999; 35: 93-7 (Pubitemid 29080239)
27. Poulakis V, Witzsch U, De Vries R, Altmannsberger HM, Manyak MJ, Becht E,. A comparison of urinary nuclear matrix protein-22 and bladder tumour antigen tests with voided urinary cytology in detecting and following BC: the prognostic value of false-positive results. BJU Int 2001; 88: 692-701
28. Lokeshwar VB, Habuchi T, Grossman HB, et al. Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology 2005; 66 (Suppl. 1): 35-63 (Pubitemid 43049608)
29. Shariat SF, Sfakianos JP, Droller MJ, Karakiewicz PI, Meryn S, Bochner BH,. The effect of age and gender on BC: a critical review of the literature. BJU Int 2010; 105: 300-8. Epub 2009 Nov 13
30. Atsü N, Ekici S, Oge OO, Ergen A, Hascelik G, Ozen H,. false-positive results of the NMP22 test due to hematuria. J Urol 2002; 167: 555-8 (Pubitemid 34074526)
31. Oosterlinck W, Lobel B, Jakse G, Malmström PU, Stöckle M, Sternberg C,. Guidelines on BC. The EAU working group on oncological urology. EurUrol 2002; 41: 105-12
32. Herr HW, Donat SM, Dalbagni G,. Correlation of cystoscopy with histology of recurrent papillary tumors of the bladder. J Urol 2002; 168: 978-80
33. Shariat SF, Marberger MJ, Lotan Y, et al. Variability in the performance of nuclear matrix protein 22 for the detection of BC. J Urol 2006; 176: 919-26; discussion 926 (Pubitemid 44160707)